Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Prenetics Global Limited (PRE:NASDAQ), powered by AI.
Prenetics Global Limited is currently trading at $21.63. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Prenetics Global Limited on Alpha Lenz.
View Prenetics Global Limited's valuation metrics on Alpha Lenz.
“Prenetics Global Limited's ROE is -23.1%. Explore profitability and growth together.”
Ask for details →Prenetics Global Limited is a biotechnology company specializing in genetic and diagnostic testing services. It plays a pivotal role in the healthcare sector by utilizing advanced technology to offer a variety of solutions aimed at improving and personalizing patient care. Prenetics provides genetic testing that helps individuals understand their predisposition to certain health conditions, enabling proactive healthcare decisions. Additionally, their diagnostic services, such as rapidly accessible COVID-19 testing kits, have been critical during health crises, showcasing the company's ability to swiftly meet public health needs. By bridging technology and medicine, Prenetics impacts industries spanning healthcare, biotechnology, and consumer health products. With headquarters in Hong Kong and a global reach, it underscores the importance of precision medicine in modern healthcare, catering to both individuals and businesses seeking reliable and accurate health data. Through innovation and strategic partnerships, Prenetics fortifies its position as a key player in the genetic testing and diagnostics fields, significantly influencing the way health data is collected, analyzed, and applied.
“Prenetics Global Limited's ROE is -23.1%. Explore profitability and growth together.”
Ask for details →Prenetics Global Limited (ticker: PRE) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 285 employees.
The current price is $21.63 with a P/E ratio of -x and P/B of -x.
ROE is -23.07% and operating margin is -41.27%. Annual revenue is $92M.